


## Supplementary Information

### ERpred: A web server for the prediction of subtype-specific estrogen receptor antagonists

Nalini Schaduangrat, Aijaz Ahmad Malik, Chanin Nantasenamat\*

*Center of Data Mining and Biomedical Informatics, Faculty of Medical Technology, Mahidol University, Bangkok 10700, Thailand*

#### 1. Top 10 active and inactive compounds of ER $\alpha$




**Supplementary Figure S1.** Top 10 active and inactive compounds of ER $\alpha$ . Chemical compounds of the top 10 active (A) and inactive (B) compounds for ER $\alpha$  are shown. They are represented with numbers in parentheses while their corresponding IUPAC names are in text.

The set of ER $\alpha$  actives includes (4-(4-(4-chlorophenyl)piperazin-1-yl)phenyl)(6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl)methanone (**1**), 6-phenyl-5-(4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5,6,7,8-tetrahydronaphthalen-2-ol (**2**), (5R,6S)-5-(4-(2-((R)-3-methylpyrrolidin-1-yl)ethoxy)phenyl)-6-phenyl-5,6,7,8-tetrahydronaphthalen-2-ol (**3**), (2S,3R)-2-(4-(2-(2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)ethoxy)phenyl)-3-(4-hydroxyphenyl)-2,3-dihydrobenzo[b][1,4]oxathiin-6-ol (**4**), (S)-5-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-5,11-dihydrochromeno[4,3-c]chromene-2,8-diol (**5**), (S)-2-(4-hydroxyphenyl)-3-methyl-1-(4-(2-(pyrrolidin-1-yl)propoxy)benzyl)-1H-indol-5-ol (**6**), (2S,3R)-2-(4-(2-(2,2-dimethylpyrrolidin-1-yl)ethoxy)phenyl)-3-(4-hydroxyphenyl)-2,3-dihydrobenzo[b][1,4]oxathiin-6-ol (**7**), (2S,3R)-2-(4-(2-((3R,4R)-3,4-dimethylpyrrolidin-1-yl)ethoxy)phenyl)-3-(4-hydroxyphenyl)-2,3-dihydrobenzo[b][1,4]oxathiin-6-ol (**8**), (2S,3R)-3-(4-hydroxyphenyl)-2-(4-(2-((3aR,7aS)-octahydro-2H-isoindol-2-yl)ethoxy)phenyl)-2,3-dihydrobenzo[b][1,4]oxathiin-6-ol (**9**) and (2S,3R)-2-(4-(2-((3aR,6aS)-hexahydrocyclopenta[c]pyrrol-2(1H)-yl)ethoxy)phenyl)-3-(4-hydroxyphenyl)-2,3-dihydrobenzo[b][1,4]oxathiin-6-ol (**10**).

The set of ER $\alpha$  inactive includes 7-hydroxy-3-(4-hydroxyphenyl)quinazolin-4(3H)-one (**11**), (R)-2-(4-hydroxyphenyl)chroman-7-ol (**12**), 5,7-dihydroxy-3-(4-hydroxyphenyl)-6-propylquinazolin-4(3H)-one (**13**), 3-((3,4-dimethylphenoxy)methyl)furan-2-carboxylic acid (**14**),

N-cyclohexyl-2-((8-methoxy-6-oxo-6H-benzo[c]chromen-3-yl)oxy)acetamide (**15**), 5,7-dihydroxy-3-(4-hydroxyphenyl)-2-methylquinazolin-4(3H)-one (**16**), 2-(2-(4-ethyl-4-methyl-2,5-dioxoimidazolidin-1-yl)acetamido)-5,6-dihydro-4H-cyclopenta[b]thiophene-3-carboxamide (**17**), 3-(3-chloro-4-hydroxyphenyl)-5,7-dihydroxyquinazolin-4(3H)-one (**18**), 3-(3-fluoro-4-hydroxyphenyl)-5,7-dihydroxyquinazolin-4(3H)-one (**19**) and 2-((furan-2-ylmethyl)amino)-2-oxoethyl 3-((3,4-dihydroisoquinolin-2(1H)-yl)sulfonyl)benzoate (**20**).

## 2. Top 10 active and inactive compounds of Er $\beta$



**Supplementary Figure S2.** Top 10 active and inactive compounds of ER $\beta$ . Chemical compounds of the top 10 active (A) and inactive (B) compounds for ER $\beta$  are shown. They are represented with numbers in parentheses while their corresponding IUPAC names are in text.

Chemical compounds of the top 10 active (A) and inactive (B) compounds for ER $\beta$  are shown in Supplementary Figure S2. They are represented with numbers in parentheses while their corresponding IUPAC names are as follows. The set of ER $\beta$  active includes 4-(8-fluoro-5-(4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-2,3-dihydrobenzo[b]oxepin-4-yl)phenol (21), (5R,6S)-6-phenyl-5-(4-((S)-2-(pyrrolidin-1-yl)propoxy)phenyl)-5,6,7,8-tetrahydronaphthalen-2-ol (22), (R)-9a-butyl-6-(trifluoromethyl)-9,9a-dihydroindeno[2,1-e]indazole-7,10(3H,8H)-dione (23), (R)-1-(2-(4-(5,11-dihydroxy-1,8-dihydro-2H-

benzo[2,3]oxepino[4,5-c]chromen-8-yl)phenoxy)ethyl)pyrrolidine-2,5-dione (**24**), (S)-9a-butyl-6-ethyl-1-fluoro-8,9,9a,10-tetrahydroindeno[2,1-e]indazol-7(3H)-one (**25**), (S)-9a-ethyl-1-fluoro-6-(trifluoromethyl)-8,9,9a,10-tetrahydroindeno[2,1-e]indazol-7(3H)-one (**26**), 3-(2-fluoro-4-hydroxyphenyl)-7-hydroxy-1-naphthonitrile (**27**), 4-bromo-2-(4-hydroxyphenyl)-7-methoxybenzofuran-5-ol (**28**), (5R,6S)-5-(4-((R)-3-methylpyrrolidin-1-yl)ethoxy)phenyl)-6-phenyl-5,6,7,8-tetrahydronaphthalen-2-ol (**29**) and 7-bromo-2-(3-fluoro-4-hydroxyphenyl)benzofuran-5-ol (**30**).

The set of ER $\beta$  inactive includes 2-((2-(2,4-dimethylphenyl)-2-oxoethyl)thio)-4-(furan-2-yl)-6-oxo-1,4,5,6-tetrahydropyridine-3-carbonitrile (**31**), (E)-4-(((4-morpholinophenyl)imino)methyl)benzene-1,3-diol (**32**), ethyl(E)-7-amino-6-cyano-8-(2-methoxybenzylidene)-3-(2-methoxyphenyl)-4-oxo-3,4-dihydro-8H-pyrrolo[2,1-c][1,4]thiazine-1-carboxylate (**33**), (1,4-dioxa-8-azaspiro[4.5]decan-8-yl)(5-(tosylmethyl)furan-2-yl)methanone (**34**), N-(3-amino-4-methoxyphenyl)furan-2-carboxamide (**35**), 2-(benzofuran-2-yl)-1-(2,4-dihydroxyphenyl)ethan-1-one (**36**), 1-allyl-2,5-dioxo-1,5-dihydro-2H-dipyrido[1,2-a:2',3'-d]pyrimidine-3-carbonitrile (**37**), 2-((5-(4-(difluoromethoxy)phenyl)-1,3,4-oxadiazol-2-yl)thio)-N-((furan-2-ylmethyl)carbamoyl)acetamide (**38**), methyl 5-(furan-2-yl)-7-(trifluoromethyl)pyrazolo[1,5-a]pyrimidine-3-carboxylate (**39**) and 1-(dimethylamino)-1-oxopropan-2-yl 2-(4-chloro-2-methylphenoxy)acetate (**40**).